— Biotechnology company Amicus Therapeutics (NASDAQ: FOLD) reported a net loss of $356.4 million or $1.48 per share for fiscal 2019, compared to a loss of $349 million or $1.88 per share in the preceding year.
— Total revenues nearly doubled to $182.2 billion in 2019 from $91.25 million in 2018
— Adjusted operating expenses were $464.3 million in 2019, up 14% compared to fiscal 2018
— Expects revenues of Galafold, a therapy for Fabry disease in adults, to be in the range of $250 million to $260 million in fiscal 2020
— Estimates full-year operating expense to be in the range of $410 million to $420 million, which represents an increase from last year
— On track to continue ongoing operations well into 2022, making use of the current cash position
— Looks to complete Pompe Phase-3 PROPEL study, enroll pediatric studies and advance manufacturing to support 2021 BLA and MAA
Most Popular
Richtech’s mission is to transform the service industry through collaborative robotic solutions: President
Richtech Robotics Inc. (NASDAQ: RR) is a leading provider of robotic solutions, developing, manufacturing, and deploying novel products needed for automation in the service industry. The company's solutions include delivery,
What to expect when Darden Restaurants reports Q1 results
Darden Restaurants, Inc. (NYSE: DRI) is scheduled to release its first-quarter report on September 19, with analysts forecasting a year-over-year increase in sales and profit. The market will be keeping a
Oracle (ORCL) sees continued strong revenue growth in FY25
Oracle Corporation (NYSE: ORCL) started the new fiscal year on a high note with stronger-than-expected first-quarter results, driving the stock higher soon after the announcement. The tech giant’s earnings and
